May 16, 2018 / 9:16 PM / 4 months ago

BRIEF-Genentech Says Follow-Up Phase 3 Data Showed Alecensa Reduced Risk Of Disease Progression By 57 Pct

May 16 (Reuters) - Genentech:

* FOLLOW-UP PHASE III DATA SHOWED GENENTECH’S ALECENSA HELPED PEOPLE WITH ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER LIVE A MEDIAN OF ALMOST THREE YEARS WITHOUT THEIR DISEASE WORSENING OR DEATH

* GENENTECH - FOLLOW-UP PHASE III DATA SHOWED ALECENSA REDUCED RISK OF DISEASE PROGRESSION/DEATH BY 57 PERCENT VERSUS CRIZOTINIB IN PEOPLE WITH ALK-POSITIVE METASTATIC NSCLC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below